Cargando…

A New Era in Ocular Therapeutics: Advanced Drug Delivery Systems for Uveitis and Neuro-Ophthalmologic Conditions

The eye’s intricate anatomical barriers pose significant challenges to the penetration, residence time, and bioavailability of topically applied medications, particularly in managing uveitis and neuro-ophthalmologic conditions. Addressing this issue, polymeric nano-based drug delivery systems (DDS)...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Kevin Y., Tan, Kenneth, Akbar, Dania, Choulakian, Mazen Y., Tran, Simon D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10385446/
https://www.ncbi.nlm.nih.gov/pubmed/37514137
http://dx.doi.org/10.3390/pharmaceutics15071952
_version_ 1785081409241612288
author Wu, Kevin Y.
Tan, Kenneth
Akbar, Dania
Choulakian, Mazen Y.
Tran, Simon D.
author_facet Wu, Kevin Y.
Tan, Kenneth
Akbar, Dania
Choulakian, Mazen Y.
Tran, Simon D.
author_sort Wu, Kevin Y.
collection PubMed
description The eye’s intricate anatomical barriers pose significant challenges to the penetration, residence time, and bioavailability of topically applied medications, particularly in managing uveitis and neuro-ophthalmologic conditions. Addressing this issue, polymeric nano-based drug delivery systems (DDS) have surfaced as a promising solution. These systems enhance drug bioavailability in hard-to-reach target tissues, extend residence time within ocular tissues, and utilize biodegradable and nanosized polymers to reduce undesirable side effects. Thus, they have stimulated substantial interest in crafting innovative treatments for uveitis and neuro-ophthalmologic diseases. This review provides a comprehensive exploration of polymeric nano-based DDS used for managing these conditions. We discuss the present therapeutic hurdles posed by these diseases and explore the potential role of various biopolymers in broadening our treatment repertoire. Our study incorporates a detailed literature review of preclinical and clinical studies from 2017 to 2023. Owing to advancements in polymer science, ocular DDS has made rapid strides, showing tremendous potential to revolutionize the treatment of patients with uveitis and neuro-ophthalmologic disorders.
format Online
Article
Text
id pubmed-10385446
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103854462023-07-30 A New Era in Ocular Therapeutics: Advanced Drug Delivery Systems for Uveitis and Neuro-Ophthalmologic Conditions Wu, Kevin Y. Tan, Kenneth Akbar, Dania Choulakian, Mazen Y. Tran, Simon D. Pharmaceutics Review The eye’s intricate anatomical barriers pose significant challenges to the penetration, residence time, and bioavailability of topically applied medications, particularly in managing uveitis and neuro-ophthalmologic conditions. Addressing this issue, polymeric nano-based drug delivery systems (DDS) have surfaced as a promising solution. These systems enhance drug bioavailability in hard-to-reach target tissues, extend residence time within ocular tissues, and utilize biodegradable and nanosized polymers to reduce undesirable side effects. Thus, they have stimulated substantial interest in crafting innovative treatments for uveitis and neuro-ophthalmologic diseases. This review provides a comprehensive exploration of polymeric nano-based DDS used for managing these conditions. We discuss the present therapeutic hurdles posed by these diseases and explore the potential role of various biopolymers in broadening our treatment repertoire. Our study incorporates a detailed literature review of preclinical and clinical studies from 2017 to 2023. Owing to advancements in polymer science, ocular DDS has made rapid strides, showing tremendous potential to revolutionize the treatment of patients with uveitis and neuro-ophthalmologic disorders. MDPI 2023-07-14 /pmc/articles/PMC10385446/ /pubmed/37514137 http://dx.doi.org/10.3390/pharmaceutics15071952 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Wu, Kevin Y.
Tan, Kenneth
Akbar, Dania
Choulakian, Mazen Y.
Tran, Simon D.
A New Era in Ocular Therapeutics: Advanced Drug Delivery Systems for Uveitis and Neuro-Ophthalmologic Conditions
title A New Era in Ocular Therapeutics: Advanced Drug Delivery Systems for Uveitis and Neuro-Ophthalmologic Conditions
title_full A New Era in Ocular Therapeutics: Advanced Drug Delivery Systems for Uveitis and Neuro-Ophthalmologic Conditions
title_fullStr A New Era in Ocular Therapeutics: Advanced Drug Delivery Systems for Uveitis and Neuro-Ophthalmologic Conditions
title_full_unstemmed A New Era in Ocular Therapeutics: Advanced Drug Delivery Systems for Uveitis and Neuro-Ophthalmologic Conditions
title_short A New Era in Ocular Therapeutics: Advanced Drug Delivery Systems for Uveitis and Neuro-Ophthalmologic Conditions
title_sort new era in ocular therapeutics: advanced drug delivery systems for uveitis and neuro-ophthalmologic conditions
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10385446/
https://www.ncbi.nlm.nih.gov/pubmed/37514137
http://dx.doi.org/10.3390/pharmaceutics15071952
work_keys_str_mv AT wukeviny anewerainoculartherapeuticsadvanceddrugdeliverysystemsforuveitisandneuroophthalmologicconditions
AT tankenneth anewerainoculartherapeuticsadvanceddrugdeliverysystemsforuveitisandneuroophthalmologicconditions
AT akbardania anewerainoculartherapeuticsadvanceddrugdeliverysystemsforuveitisandneuroophthalmologicconditions
AT choulakianmazeny anewerainoculartherapeuticsadvanceddrugdeliverysystemsforuveitisandneuroophthalmologicconditions
AT transimond anewerainoculartherapeuticsadvanceddrugdeliverysystemsforuveitisandneuroophthalmologicconditions
AT wukeviny newerainoculartherapeuticsadvanceddrugdeliverysystemsforuveitisandneuroophthalmologicconditions
AT tankenneth newerainoculartherapeuticsadvanceddrugdeliverysystemsforuveitisandneuroophthalmologicconditions
AT akbardania newerainoculartherapeuticsadvanceddrugdeliverysystemsforuveitisandneuroophthalmologicconditions
AT choulakianmazeny newerainoculartherapeuticsadvanceddrugdeliverysystemsforuveitisandneuroophthalmologicconditions
AT transimond newerainoculartherapeuticsadvanceddrugdeliverysystemsforuveitisandneuroophthalmologicconditions